Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals, Inc. (ARMP) EBITDA (2016 - 2018)

Armata Pharmaceuticals' EBITDA history spans 6 years, with the latest figure at -$1.1 million for Q4 2018.

  • For Q4 2018, EBITDA rose 53.45% year-over-year to -$1.1 million; the TTM value through Dec 2018 reached -$16.1 million, up 0.51%, while the annual FY2024 figure was -$42.4 million, 3.78% down from the prior year.
  • EBITDA for Q4 2018 was -$1.1 million at Armata Pharmaceuticals, up from -$8.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $19.3 million in Q3 2014 and bottomed at -$16.1 million in Q4 2016.
  • The 5-year median for EBITDA is -$2.8 million (2014), against an average of -$2.4 million.
  • The largest annual shift saw EBITDA soared 221.59% in 2014 before it plummeted 1073.86% in 2018.
  • A 5-year view of EBITDA shows it stood at -$2.6 million in 2014, then rose by 6.51% to -$2.4 million in 2015, then plummeted by 562.73% to -$16.1 million in 2016, then surged by 85.3% to -$2.4 million in 2017, then surged by 53.45% to -$1.1 million in 2018.
  • Per Business Quant, the three most recent readings for ARMP's EBITDA are -$1.1 million (Q4 2018), -$8.8 million (Q3 2018), and -$3.2 million (Q2 2018).